BioNTech updates Phase 2/3 trial of BNT113 cancer immunotherapy
BioNTech provided an update on its Phase 2/3 clinical trial of BNT113, an mRNA cancer immunotherapy candidate for metastatic HPV16-positive head and neck cancer.
Story updates
10:47:41 AM UTC
SquawkNews
MAINZ, Germany, October 13, 2026 — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the first topline results from the AHEAD-MERIT Phase 2/3 clinical trial (NCT04534205) for its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran or “tenu-ra”).The clini…
10:48:00 AM UTC
SquawkNews
BioNTech reported the BNT113 plus pembrolizumab arm did not show a statistically significant PFS benefit vs pembrolizumab alone in the AHEAD-MERIT Phase 2/3 trial. The IDMC recommended the study continue as planned to assess overall survival.Material DetailsContext by AI AnalystThis is a mid-stage…